Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research Annual Meeting 2026
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm Programs
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
SAGA Metals Reports Assays from R-0030 to R-0035 with Intercepts Including 48.03% Fe2O3, 7.25% TiO2, 0.304% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
